MPM BioVentures 2014, L.P. sold 259,837 Entrada Therapeutics shares at $7.11 to $7.41 per share between Sep. 4 and Sep. 9, 2026. The insider’s reported post-sale ownership was 3,885,115 shares, giving investors the disclosed sale size, price range and remaining stake.
Key Highlights
- MPM BioVentures 2014, L.P. reported ownership of 3,885,115 shares after the transactions.
- All sale entries carried transaction code S, denoting open-market sales in insider reporting.
- MPM BioVentures 2018, L.P. also appears in the transaction description as an insider of Entrada Therapeutics.
Entrada Therapeutics, Inc. (NASDAQ: TRDA) saw MPM BioVentures 2014, L.P. sell 259,837 shares at prices ranging from $7.11 to $7.41 per share between Sep. 4 and Sep. 9, 2026. The activity covered separate sales recorded during that period.
Insider Ownership Stands
The reported sale total was divided across separate transactions rather than presented as one block. The price range applies to the shares sold, with individual transaction prices spanning $7.11 to $7.41 per share. The transaction description also names MPM BioVentures 2018, L.P. as an insider of Entrada Therapeutics.
FAQs
Q: How many Entrada Therapeutics shares did MPM BioVentures sell?
A: MPM BioVentures 2014, L.P. sold 259,837 Entrada Therapeutics shares. The transactions were priced from $7.11 to $7.41 per share between Sep. 4 and Sep. 9, 2026.
Q: What was MPM BioVentures’ remaining TRDA ownership?
A: MPM BioVentures 2014, L.P. owned 3,885,115 Entrada Therapeutics shares after the reported sales. That figure represents the stated post-transaction ownership balance.
Q: What does transaction code S mean for the Entrada Therapeutics sale?
A: Transaction code S identifies each reported entry as part of the sale activity. For Entrada Therapeutics, those entries covered the 259,837 shares sold by MPM BioVentures 2014, L.P.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.